JP2000506861A5 - - Google Patents

Download PDF

Info

Publication number
JP2000506861A5
JP2000506861A5 JP1997532601A JP53260197A JP2000506861A5 JP 2000506861 A5 JP2000506861 A5 JP 2000506861A5 JP 1997532601 A JP1997532601 A JP 1997532601A JP 53260197 A JP53260197 A JP 53260197A JP 2000506861 A5 JP2000506861 A5 JP 2000506861A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997532601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000506861A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/002295 external-priority patent/WO1997033858A1/en
Publication of JP2000506861A publication Critical patent/JP2000506861A/ja
Publication of JP2000506861A5 publication Critical patent/JP2000506861A5/ja
Ceased legal-status Critical Current

Links

JP9532601A 1996-03-14 1997-02-18 医薬としての新規な置換環状アミノ酸 Ceased JP2000506861A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1343296P 1996-03-14 1996-03-14
US60/013,432 1996-03-14
PCT/US1997/002295 WO1997033858A1 (en) 1996-03-14 1997-02-18 Novel substituted cyclic amino acids as pharmaceutical agents

Publications (2)

Publication Number Publication Date
JP2000506861A JP2000506861A (ja) 2000-06-06
JP2000506861A5 true JP2000506861A5 (enExample) 2004-11-25

Family

ID=21759938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9532601A Ceased JP2000506861A (ja) 1996-03-14 1997-02-18 医薬としての新規な置換環状アミノ酸

Country Status (29)

Country Link
US (1) US6103932A (enExample)
EP (1) EP0888286B1 (enExample)
JP (1) JP2000506861A (enExample)
KR (1) KR100512506B1 (enExample)
AT (1) ATE207878T1 (enExample)
AU (1) AU734173B2 (enExample)
BG (1) BG63662B1 (enExample)
BR (1) BR9708200A (enExample)
CA (1) CA2244912C (enExample)
CZ (1) CZ293759B6 (enExample)
DE (1) DE69707842T2 (enExample)
DK (2) DK0888285T3 (enExample)
EA (1) EA002765B1 (enExample)
EE (1) EE9800309A (enExample)
ES (1) ES2167717T3 (enExample)
GE (1) GEP20012413B (enExample)
HU (1) HU224720B1 (enExample)
IL (1) IL125544A (enExample)
IS (1) IS1990B (enExample)
MX (1) MX9806069A (enExample)
NO (1) NO984205L (enExample)
NZ (1) NZ331143A (enExample)
PL (1) PL185991B1 (enExample)
PT (1) PT888286E (enExample)
SK (1) SK283295B6 (enExample)
TR (1) TR199801807T2 (enExample)
UA (1) UA49011C2 (enExample)
WO (1) WO1997033858A1 (enExample)
ZA (1) ZA972200B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
DE69834204T2 (de) 1997-10-27 2007-03-29 Warner-Lambert Co. Llc Zyklische aminosäuren und deren derivate als arzneimittel
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
ES2227896T3 (es) * 1997-12-16 2005-04-01 Warner-Lambert Company Llc Derivados de 1-aminometil-cicloalcanos sustituidos en 1 (=analogos de gabapentina), su preparacion y su uso en el tratamiento de trastornos neurologicos.
US6326374B1 (en) 1998-07-09 2001-12-04 Warner-Lambert Company Compositions comprising GABA analogs and caffeine
EP1031350A1 (en) * 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
WO2001042191A1 (en) * 1999-12-08 2001-06-14 Warner-Lambert Company Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
AU2001247762A1 (en) * 2000-03-28 2001-10-08 Delorenzo, Robert, J Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
DE10048715A1 (de) * 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
WO2002032376A2 (en) * 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6683112B2 (en) * 2000-10-24 2004-01-27 Andrx Corporation Gabapentin prodrugs and formulations
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
ES2209674T1 (es) 2000-11-02 2004-07-01 Teva Pharmaceutical Industries Ltd. Procedimiento mejorado para la preparacion de intermediarios de gabapentina.
US20040063994A1 (en) * 2001-03-16 2004-04-01 Paolo Rossi Process for the preparation of cyclic amino acids
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) * 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
US20050153928A1 (en) * 2002-05-07 2005-07-14 Holick Michael F. Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2004052360A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
BR0316572A (pt) 2002-12-13 2005-10-04 Warner Lambert Co Ligando alfa-2-delta para o tratamento de sintomas do trato variáveis inferior, utilização e produto deste
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
JP2006522146A (ja) * 2003-03-31 2006-09-28 ゼノポート,インコーポレイティド Gaba類似体のプロドラッグを使用するのぼせの治療または予防
JP2007505149A (ja) 2003-09-11 2007-03-08 ゼノポート,インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および/あるいは予防
ES2334673T3 (es) 2003-09-12 2010-03-15 Pfizer Inc. Combinaciones que comprenden ligandos alfa-2-delta e inhibidores de recaptacion de serotonina/noradrenalina.
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
SI1677767T1 (sl) * 2003-10-14 2011-11-30 Xenoport Inc Kristalinična oblika analoga gama-aminomaslene kisline
CA2548917C (en) 2003-12-11 2014-09-23 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US7632864B2 (en) * 2004-03-17 2009-12-15 Hikal Ltd. Gabapentin analogues and process thereof
US20050209332A1 (en) * 2004-03-17 2005-09-22 Hikal Limited Gabapentin analogues and process thereof
EP2172445A1 (en) 2004-03-17 2010-04-07 Hikal Limited Cis (z) 4-t-butylgabapentin and its synthesis
CN101068538A (zh) 2004-11-04 2007-11-07 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
CA2672044A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
HRP20110634T1 (hr) 2006-12-22 2011-10-31 Recordati Ireland Limited KOMBINIRANA TERAPIJA LIGANADA α<SUB>2</SUB>δ I NSAID ZA POREMEĆAJE DONJEG URINARNOG TRAKTA
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
JP5291123B2 (ja) * 2008-01-25 2013-09-18 ゼノポート,インコーポレイティド (3s)−アミノメチル−5−ヘキサン酸プロドラッグの結晶形態及びその使用
BRPI0919811B1 (pt) 2008-10-08 2022-04-19 Xgene Pharmaceutical Inc Conjugados de gaba e métodos de uso dos mesmos
WO2010048423A1 (en) 2008-10-24 2010-04-29 Ark Diagnostics, Inc. Levetiracetam immunoassays
EP2400989B1 (en) * 2009-02-24 2016-08-10 Nektar Therapeutics Gabapentin-peg conjugates
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
WO2014113717A1 (en) 2013-01-18 2014-07-24 Ark Diagnostics, Inc. Voriconazole immunoassays
US10130715B2 (en) 2013-01-28 2018-11-20 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor
US9920136B2 (en) 2013-02-13 2018-03-20 Ark Diagnostics, Inc. Posaconazole immunoassays
CA3099775A1 (en) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2543821C2 (de) * 1974-12-21 1984-10-18 Gödecke AG, 1000 Berlin Bestimmte Salze und Ester von 1-Aminomethyl-1-cycloalkanessigsäuren und diese Verbindungen enthaltende Arzneimittel
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
DE2626467C2 (de) * 1976-06-12 1984-11-22 Gödecke AG, 1000 Berlin 1-(N-Isopropylaminomethyl)-cyclohexanessigsäure, Verfahren zu deren Herstellung und diese Verbindung enthaltende Arzneimittel
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
US5098931A (en) * 1989-08-31 1992-03-24 Merck & Co., Inc. 7-substituted HMG-CoA reductase inhibitors
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
FI905584A7 (fi) * 1989-11-16 1991-05-17 Lonza Ag Menetelmä 1-(aminometyyli)sykloheksaanietikkahapon valmistamiseksi
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
IE910913A1 (en) * 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
FR2691146B1 (fr) * 1992-05-15 1998-01-02 Adir Nouveaux derives d'acides alcenecarboxyliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ES2116587T3 (es) * 1993-03-04 1998-07-16 Pfizer Derivados espiroazaciclicos como antagonistas de la sustancia p.
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic

Similar Documents

Publication Publication Date Title
JP2000506990A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2001513078A5 (enExample)
JP2001506815A5 (enExample)
JP2000501324A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000506861A5 (enExample)
JP2000500874A5 (enExample)
JP2001501394A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000508610A5 (enExample)
JP2000501744A5 (enExample)
JP2001506178A5 (enExample)
JP2000501229A5 (enExample)